KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Account Payables (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Change in Account Payables for 8 consecutive years, with -$12.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 233.76% year-over-year to -$12.4 million, compared with a TTM value of $20.9 million through Dec 2025, up 68.26%, and an annual FY2025 reading of $20.9 million, up 68.26% over the prior year.
  • Change in Account Payables was -$12.4 million for Q4 2025 at Esperion Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $27.8 million in Q1 2025 and bottomed at -$21.6 million in Q1 2021.
  • Average Change in Account Payables over 5 years is $676600.0, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Change in Account Payables tumbled 2242.74% in 2022, then skyrocketed 907.07% in 2025.
  • Year by year, Change in Account Payables stood at -$3.3 million in 2021, then soared by 236.99% to $4.5 million in 2022, then increased by 23.02% to $5.5 million in 2023, then skyrocketed by 69.04% to $9.3 million in 2024, then crashed by 233.76% to -$12.4 million in 2025.
  • Business Quant data shows Change in Account Payables for ESPR at -$12.4 million in Q4 2025, $2.9 million in Q3 2025, and $2.6 million in Q2 2025.